恶性肿瘤患者血清磷酸葡萄糖异构酶活性测定的临床意义

Cinical Significanec On Serum Glucose Phosphateisomerase Determina-Tion Of Patients With Malignant Disease

本文对４组共３００人的血清磷酸葡萄糖异构酶（ＧＰＩ）活性和癌胚抗原（ＣＥＡ）同时进行了测定，结果肺癌组、其它恶性肿瘤组患者的血清ＧＰＩ活性显著高于健康对照组和肺良性疾病组。肺癌组的阳性率为６６．７％，其它恶性肿瘤组的阳性率为４９．５％；肺癌中以小细胞癌和腺鳞癌的阳性率为高，达８０％以上，消化系肿瘤中以肝胆胰恶性肿瘤的阳性率较高，达７８％以上。ＧＰＩ活性的敏感度高于ＣＥＡ，而ＣＥＡ的特异性高于ＧＰＩ，两者联合应用，可提高肺癌患者的诊断效率和正确诊断率。文章对ＧＰＩ活性作为肺癌标记物的地位和临床应用价值进行了讨论，认为血清ＧＰＩ活性的测定方法简便，可靠和价廉。

It Was Measured That Serum Glucose Phosphateisomerase(GPI) Activity And Carcinoemb-Ryonic Antigen(CEA) Of 300 Subjects Which Was Dlvided Into 4 Groups At Same Time. Serum GPIAnd CEA Were Higher Significantly In Patients With Lung Cancer And Malignant Diseases Than ThoseIn A Control Group Of Healthy Subjects And Bening Diseases Group. 66.7% Positive Rate In LungCancer Group And 49.5% In Other Malignant Diseases Group Were Reported Respectively. The Posi-Tive Rate In Small Cell Lung Cancer Andin Sguamous Cell Lung Cancer Were More Than 80% EspeCially. GPI Sensitivity Was Higher Than CEA And CEA Specificity Was Higher Than GPI. The Dia-Gnostic Efficiency And Correct Diagnostic Rate Can Be Increased By Combine Applying Both. Evalua-Ting GPI As A Lung Cancer Marker Was Discussed.